This market study on
Bacteriophages Therapy Market covers The market study conducted in this report analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors in the industry. Also, it sheds light on the wide-ranging competitive landscape of the global Bacteriophages Therapy market. It defines about the recent innovations, applications and end users of the market.The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on. The challenges led by the COVID-19 pandemic, leading to a decline in demand, and several initiatives taken by the government are studied in this report. The wide range of end-use applications, Heat Pumps major types, revenue, and distributors are stated. The regional analysi
Share this article
Share this article
ResearchAndMarkets.com s offering.
Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market.
We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play.
This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And the publisher summarizes what technologies they are using.
British pharma company GlaxoSmithKline (GSK) are to pair up with Eligo Bioscience in a deal potentially worth €185m ($224m) that sees the firms target the microbiome to reduce the risk of developing acne.
The agreement terms provide Eligo with an upfront payment along with R&D funding to develop EB005, the Paris-based firm’s discovery program for acne, until preclinical proof of concept.
Here, GSK could form a license and collaboration deal with Eligo to further develop EB005, where Eligo could receive up to €185m in license fees, milestone payments as well as royalties on global sales.
“We are excited to work with GSK on advancing our approach to address acne, combining our technology platform with GSK’s capabilities to bring innovation from the lab bench, through clinical development, and to patients,” says Xavier Duportet, Eligo’s Chief Executive Officer.
La fin de l acné, un projet français franceinter.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from franceinter.fr Daily Mail and Mail on Sunday newspapers.
Seventure Partners has been investing in microbiome innovation since the launch of its 2014 Health for Life Fund and will now extend reach of its latest fund due to so much interest (Getty Images) European life sciences investment firm Seventure Partners has extended the final close of its second microbiome innovation fund and increased focus on advances in the skin microbiome space.
Seventure Partners had been investing in microbiome innovation since the launch of its Health For Life Fund in 2014, where it invested €160m across 20 cutting-edge companies – Enterome, Vedanta Biosciences and BiomX, among others. In March 2019, Seventure Partners launched its Health For Life Fund II, making a further €200m+ available for investment in the microbiome and nutrition space – a fund that was recently extended.